Quest Diagnostics 2008 Annual Report Download - page 78

Download and view the complete annual report

Please find page 78 of the 2008 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 128

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(dollars in thousands unless otherwise indicated)
1. DESCRIPTION OF BUSINESS
Quest Diagnostics Incorporated and its subsidiaries (“Quest Diagnostics” or the “Company”) is the world’s
leading provider of diagnostic testing, information and services, providing insights that enable patients, physicians
and others to make decisions to improve health. Quest Diagnostics offers patients and physicians the broadest
access to diagnostic laboratory services through the Company’s nationwide network of laboratories and owned
patient service centers. The Company provides interpretive consultation through the largest medical and scientific
staff in the industry, with approximately 900 M.D.s and Ph.D.s primarily located in the United States. Quest
Diagnostics is the leading provider of clinical testing, including gene-based testing and other esoteric testing,
anatomic pathology services and testing for drugs-of-abuse, and the leading provider of risk assessment services
for the life insurance industry. The Company is also a leading provider of testing for clinical trials. The
Company’s diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-
care testing. Quest Diagnostics empowers healthcare organizations and clinicians with state-of-the-art information
technology solutions that can improve patient care and medical practice.
During 2008, Quest Diagnostics processed approximately 150 million requisitions through its extensive
network of laboratories in virtually every major metropolitan area throughout the United States.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include the accounts of all entities controlled by the Company through
its direct or indirect ownership of a majority voting interest and the accounts of any variable interest entities, as
defined in Financial Accounting Standards Board (“FASB”) Interpretation No. 46 “Consolidation of Variable
Interest Entities,” where the Company is subject to a majority of the risk of loss from the variable interest
entity’s activities, or entitled to receive a majority of the entity’s residual returns or both. The Company’s
relationships with variable interest entities were not material at both December 31, 2008 and 2007. Investments in
entities which the Company does not control, but in which it has a substantial ownership interest (generally
between 20% and 49%) and can exercise significant influence, are accounted for using the equity method of
accounting. As of December 31, 2008 and 2007, the Company’s investments in affiliates accounted for under the
equity method of accounting totaled $38.4 million and $37.5 million, respectively. The Company’s share of
equity earnings from investments in affiliates, accounted for under the equity method, totaled $29.7 million, $27.0
million and $28.5 million, respectively, for 2008, 2007 and 2006. All significant intercompany accounts and
transactions are eliminated in consolidation.
Basis of Presentation
During the third quarter of 2006, the Company completed its wind-down of NID, a test kit manufacturing
subsidiary, and classified the operations of NID as discontinued operations. The accompanying consolidated
statements of operations and related disclosures have been prepared to report the results of NID as discontinued
operations for all periods presented. See Note 15 for a further discussion of discontinued operations.
In addition, certain reclassifications have been made to conform to the current year presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates.
Revenue Recognition
The Company primarily recognizes revenue for services rendered upon completion of the testing process.
Billings for services reimbursed by third-party payers, including Medicare and Medicaid, are recorded as revenues
net of allowances for differences between amounts billed and the estimated receipts from such payers.
Adjustments to the estimated receipts, based on final settlement with the third-party payers, are recorded upon
F-6